Facebook Instagram X-twitter Linkedin

Cagrilintide 5mg + Semaglutide 5mg (10mg)

Table of Contents

  • Quickstart Highlights

Cagrilintide 5mg + Semaglutide 5mg (10mg) protocols combine two complementary investigational peptides designed to support appetite regulation, weight management, and metabolic health. Cagrilintide, an amylin analog, works synergistically with Semaglutide, a GLP-1 receptor agonist, to enhance satiety, reduce caloric intake, and improve glycemic control. This guide outlines a subcutaneous administration approach optimized for the 10 mg combined vial format.

  • Reconstitute: Add 2.0 mL bacteriostatic water → 5 mg Cagrilintide + 5 mg Semaglutide (5 mg/mL combined concentration)
  • Typical weekly range: 0.25–1 mg total dose, titrated gradually (subcutaneous)
  • Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 50 mcg (0.05 mg) combined dose on a U-100 insulin syringe
  • Storage: Lyophilized: store at −20 °C; after reconstitution, refrigerate at 2–8 °C and use within 2–4 weeks
  • Protocol Overview

Concise summary of the subcutaneous regimen.

  • Goal: Support weight loss, appetite control, and metabolic balance through dual amylin + GLP-1 pathway activation
  • Schedule: Once weekly subcutaneous injections (with gradual dose escalation)
  • Dose Range: 0.25–1 mg total weekly dose
  • Dosing Protocol

Suggested approach for the 10 mg combined vial format.

  • Start: 0.25 mg once weekly to assess tolerance
  • Titration: Increase gradually every 2–4 weeks (e.g., 0.25 → 0.5 → 1 mg)
  • Target: 0.5–1 mg once weekly, depending on tolerance
  • Frequency: Once per week (subcutaneous)
  • Vial Duration: One 10 mg vial can last several weeks, depending on dosing level
  • Timing: Same day each week; consistency is key
  • Mechanism of Action

Cagrilintide is a long-acting amylin analog that mimics the effects of the natural hormone amylin, which is co-secreted with insulin. It helps regulate appetite by slowing gastric emptying and promoting satiety signals in the brain.

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist that enhances insulin secretion, reduces glucagon levels, delays gastric emptying, and significantly decreases appetite.

When combined, these two compounds act on complementary pathways, amylin and GLP-1 receptors, leading to enhanced appetite suppression, improved portion control, and greater overall metabolic efficiency compared to either compound alone.

  • Potential Benefits & Side Effects

Observations based on clinical and early-stage research.

Potential Benefits:

  • May significantly reduce appetite and caloric intake
  • May support substantial weight loss
  • May improve blood glucose control and insulin sensitivity
  • The synergistic effect may enhance results compared to single-agent use

Possible Side Effects:

  • Nausea, especially during dose escalation
  • Reduced appetite (expected effect)
  • Possible fatigue or mild gastrointestinal discomfort
  • Injection-site irritation
  • Long-term safety for combined use is still being studied; use remains investigational